Malignant mixed müllerian tumor of the uterus in a patient taking raloxifene

Noah A. Goldman, Maria M. De Los Angeles, Joan G. Jones, Gary L. Goldberg

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

BACKGROUND: Uterine malignant mixed mesodermal tumor is a rare variant of uterine cancer. Data suggest that tamoxifen is involved in the pathogenesis. We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator. CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention. Diagnosis had been delayed secondary to sampling of the other uterine horn. CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor. Special attention should be paid when attempting to sample the endometrium in patients with müllerian abnormalities.

Original languageEnglish (US)
Pages (from-to)1278-1280
Number of pages3
JournalObstetrics and Gynecology
Volume105
Issue number5 II
DOIs
StatePublished - May 2005
Externally publishedYes

Fingerprint

Malignant Mixed Tumor
Uterus
Selective Estrogen Receptor Modulators
Uterine Neoplasms
Tamoxifen
Endometrium
Osteoporosis
Raloxifene Hydrochloride

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Goldman, N. A., De Los Angeles, M. M., Jones, J. G., & Goldberg, G. L. (2005). Malignant mixed müllerian tumor of the uterus in a patient taking raloxifene. Obstetrics and Gynecology, 105(5 II), 1278-1280. https://doi.org/10.1097/01.AOG.0000160480.55365.a8

Malignant mixed müllerian tumor of the uterus in a patient taking raloxifene. / Goldman, Noah A.; De Los Angeles, Maria M.; Jones, Joan G.; Goldberg, Gary L.

In: Obstetrics and Gynecology, Vol. 105, No. 5 II, 05.2005, p. 1278-1280.

Research output: Contribution to journalArticle

Goldman, NA, De Los Angeles, MM, Jones, JG & Goldberg, GL 2005, 'Malignant mixed müllerian tumor of the uterus in a patient taking raloxifene', Obstetrics and Gynecology, vol. 105, no. 5 II, pp. 1278-1280. https://doi.org/10.1097/01.AOG.0000160480.55365.a8
Goldman, Noah A. ; De Los Angeles, Maria M. ; Jones, Joan G. ; Goldberg, Gary L. / Malignant mixed müllerian tumor of the uterus in a patient taking raloxifene. In: Obstetrics and Gynecology. 2005 ; Vol. 105, No. 5 II. pp. 1278-1280.
@article{e8b79c56b60449efaf89aae743d31ca2,
title = "Malignant mixed m{\"u}llerian tumor of the uterus in a patient taking raloxifene",
abstract = "BACKGROUND: Uterine malignant mixed mesodermal tumor is a rare variant of uterine cancer. Data suggest that tamoxifen is involved in the pathogenesis. We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator. CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention. Diagnosis had been delayed secondary to sampling of the other uterine horn. CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor. Special attention should be paid when attempting to sample the endometrium in patients with m{\"u}llerian abnormalities.",
author = "Goldman, {Noah A.} and {De Los Angeles}, {Maria M.} and Jones, {Joan G.} and Goldberg, {Gary L.}",
year = "2005",
month = "5",
doi = "10.1097/01.AOG.0000160480.55365.a8",
language = "English (US)",
volume = "105",
pages = "1278--1280",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "5 II",

}

TY - JOUR

T1 - Malignant mixed müllerian tumor of the uterus in a patient taking raloxifene

AU - Goldman, Noah A.

AU - De Los Angeles, Maria M.

AU - Jones, Joan G.

AU - Goldberg, Gary L.

PY - 2005/5

Y1 - 2005/5

N2 - BACKGROUND: Uterine malignant mixed mesodermal tumor is a rare variant of uterine cancer. Data suggest that tamoxifen is involved in the pathogenesis. We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator. CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention. Diagnosis had been delayed secondary to sampling of the other uterine horn. CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor. Special attention should be paid when attempting to sample the endometrium in patients with müllerian abnormalities.

AB - BACKGROUND: Uterine malignant mixed mesodermal tumor is a rare variant of uterine cancer. Data suggest that tamoxifen is involved in the pathogenesis. We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator. CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention. Diagnosis had been delayed secondary to sampling of the other uterine horn. CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor. Special attention should be paid when attempting to sample the endometrium in patients with müllerian abnormalities.

UR - http://www.scopus.com/inward/record.url?scp=20844447333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20844447333&partnerID=8YFLogxK

U2 - 10.1097/01.AOG.0000160480.55365.a8

DO - 10.1097/01.AOG.0000160480.55365.a8

M3 - Article

C2 - 15863610

AN - SCOPUS:20844447333

VL - 105

SP - 1278

EP - 1280

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 5 II

ER -